Home
Science
MIRAM® Kit
Clinical Studies
News
Team
Careers
Contact
Press Releases
All news
Press Releases
Elypta reaches Study End in Largest Kidney Cancer Recurrence Monitoring Study
May 27, 2025
Elypta a main partner in groundbreaking pan-European hereditary multi-cancer screening project
May 19, 2025
Elypta Appoints Dr. Eva Pisa to Board of Directors
May 7, 2024
Elypta interim study results show glycosaminoglycan's potential to predict the risk of developing any-type cancer with a simple urine test
Apr 8, 2024
Elypta Receives ISO 13485:2016 Quality System Certification
Jul 5, 2023
Study in JCO Precision Oncology shows promising results supporting the use of glycosaminoglycan profiles (GAGomes) for monitoring and predicting response in patients with metastatic renal cell carcinoma
Mar 15, 2023
Double multi-cancer detection rate shown in the earliest stage using Elypta MIRAM® kit
Dec 7, 2022
Elypta raises $21 million Series A to develop metabolism-based multi-cancer early detection test
Jun 20, 2022
Elypta launches Multi-Cancer Early Detection study to measure metabolic GAGome levels in adults at high risk of cancer in collaboration with the University of Leeds and Yorkshire Cancer Research
Apr 4, 2022
Elypta launches Multi-Cancer Early Detection screening study measuring metabolic GAGome levels in asymptomatic adults
Feb 15, 2022
Pivotal AUR87A study of GAGome-based liquid biopsy for kidney cancer recurrence opens 26th site
Dec 15, 2021
Elypta extends range of GAGome-based liquid biopsy applications
Dec 8, 2021
Elypta launches research service for glycosaminoglycan profiling
Feb 3, 2021
Elypta granted US patent for its liquid biopsy method based on cancer metabolism
Jan 28, 2021
First patient enrolled in Elypta’s pioneering AUR87A renal cell carcinoma liquid biopsy trial
Feb 11, 2020
Elypta raises €6.1 million in a late seed round led by Industrifonden
Jan 23, 2020
Elypta awarded €2.35 million from Horizon 2020 SME instrument
Feb 4, 2019
